JMP Securities Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $27
Exelixis Buy Rating Affirmed on Q2 Outperformance and Positive Litigation Outlook
Morgan Stanley Sticks to Their Hold Rating for Exelixis (EXEL)
Bank of America Securities Reaffirms Their Buy Rating on Exelixis (EXEL)
Buy Rating for Exelixis: Navigating Patent Lifecycles and Bolstering Growth With a Robust Pipeline
Exelixis Analyst Ratings
Exelixis Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $28 Price Target
Hold Rating on Exelixis: Analyzing Q1 Revenue Shortfalls and Pipeline Progress
Exelixis Analyst Ratings
RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept
Exelixis (EXEL) Receives a Buy From Bank of America Securities
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Zynex (ZYXI)
Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), Cyclo Therapeutics (CYTH)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)
Exelixis Analyst Ratings
Barclays Downgrades Exelixis (EXEL) to a Hold
Exelixis Analyst Ratings
Buy Rating for Exelixis Amidst Positive Litigation Outlook and Cabozantinib Sales Performance
Analysts Offer Insights on Healthcare Companies: Surrozen (SRZN), Exelixis (EXEL) and Axsome Therapeutics (AXSM)